Drug Profile
MEDI 9090
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (IV, Infusion)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
- 26 Feb 2020 MEDI 9090 is still in phase I trials for Solid Tumors in USA